Sotatercept safe and effective across cardiac index groups

PHA Canada
Dec 18, 2024
1 min read

Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size (litres per minute per square metre), instead of just cardiac output (litres per minute). A study looked at data from both the PULSAR and STELLAR trials for sotatercept and found that, compared to placebo, sotatercept improved 6-minute walk distance consistently and was equally safe for people in all cardiac index groups.

Click here to read the paper in the Journal of Heart and Lung Transplantation

Recent Posts

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

AI May Help Predict PAH Patients' Risk of Worsening

Researchers looked at the medical records of 455 people with pulmonary arterial hypertension (PAH) to find factors associated with getting worse. Using a machine-learning computer model, they found 11

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d

Comments